Sanofi (SAN) discontinues Phase 3 CIDP trial after efficacy concerns
French pharmaceutical giant Sanofi announced on June 10 the discontinuation of its Phase 3 MOBILIZE study for riliprubart, a treatment targeting chronic inflammatory demyelinating polyneuropathy (CIDP). The decision stemmed from an interim analysis revealing insufficient efficacy. Sanofi (SAN) shares are trading down 0.4% at €75.70 on June 11.
Despite the programme's termination, the company confirmed that no safety concerns were identified regarding riliprubart. Sanofi also reiterated that its financial forecasts for the 2026 fiscal year remain unchanged, indicating that this development does not alter its short-term outlook.
This announcement follows a week of varied movements for the stock. Sanofi's shares had already fallen 1.3% yesterday, June 10, closing at €76.01. Earlier, on June 8, the stock saw a 0.5% decline following EU approval for Sarclisa. These fluctuations came after a positive note from Jefferies on June 4, which reaffirmed its 'Buy' recommendation on the stock, leading to a 3.1% rise.
Why a Clinical Trial Halt Weighs on Sanofi
Sanofi, a major French pharmaceutical company, focuses on the research, development, and commercialisation of innovative therapeutic solutions. They bring a range of products, from vaccines to specialised medicines and consumer health items, to millions of patients and healthcare professionals worldwide. Their revenue primarily comes from the sales of patented treatments and their widely used consumer health portfolio.
Today's share price movement stems directly from Sanofi's announcement on 10 June 2026, that it has stopped its Phase 3 clinical trial, MOBILIZE, for the drug riliprubart. This medication was being evaluated for chronic inflammatory demyelinating polyneuropathy (CIDP). An interim analysis revealed the treatment simply wasn't effective enough, leading the company to abandon the programme, despite assurances of no safety concerns and maintained financial forecasts for 2026.
As a direct consequence of this news, Sanofi's share price is currently trading at €75.70, reflecting a 0.4% decline from yesterday's close of €76.01.
Consider a film studio investing heavily in a blockbuster movie, spending years and millions on production, only to realise during a crucial test screening that the story doesn't resonate with audiences. Despite the significant investment and effort, the studio must scrap the project, accepting the loss of funds and the absence of future box office revenue from that particular film.
Sanofi
Sanofi (SAN) is a global pharmaceutical company focused on developing, manufacturing, and marketing a diverse range of therapeutic solutions across the United States, Europe, and other international markets. Its operations are structured into three key segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals division offers specialised treatments, including monoclonal antibodies, therapies for multiple sclerosis, neurological conditions, inflammatory and rare diseases, oncology, and rare blood disorders, alongside diabetes medications and established cardiovascular products. The Vaccines segment provides immunisations for poliomyelitis, pertussis, influenza, and meningitis, among others. Its Consumer Healthcare portfolio encompasses products for allergies, coughs and colds, pain relief, digestive health, and various wellness and skincare items. Sanofi also maintains a pipeline of pharmaceutical products and vaccines under development, including collaborations with GlaxoSmithKline for a COVID-19 vaccine and Stanford University School of Medicine for immunology research. Founded in 1973, Sanofi is headquartered in Paris, France.